Stock 603590 BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beijing Konruns Pharmaceutical Co.,Ltd.

Equities

603590

CNE1000036K3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
29.84 CNY +1.22% Intraday chart for Beijing Konruns Pharmaceutical Co.,Ltd. +2.54% -21.64%
Apr. 25 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 08 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 5,084 3,903 5,959 4,670 - -
Enterprise Value (EV) 1 5,084 3,903 5,959 4,670 4,670 4,670
P/E ratio 34.6 x 38.4 x 39.7 x 25.3 x 20.7 x 16.3 x
Yield - - 0.79% - - -
Capitalization / Revenue - 4.5 x 6.48 x 4.07 x 3.44 x 2.87 x
EV / Revenue - 4.5 x 6.48 x 4.07 x 3.44 x 2.87 x
EV / EBITDA - 25.3 x 33.1 x 11.3 x 13.3 x 8.46 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - 1.36 x 1.99 x 1.48 x 1.4 x 1.32 x
Nbr of stocks (in thousands) 156,491 156,491 156,491 156,491 - -
Reference price 2 32.49 24.94 38.08 29.84 29.84 29.84
Announcement Date 4/22/22 4/25/23 4/8/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 866.7 920 1,146 1,358 1,627
EBITDA 1 - 154 179.9 414 352 552
EBIT 1 - 140.7 143.3 205.3 290 358
Operating Margin - 16.23% 15.57% 17.92% 21.36% 22%
Earnings before Tax (EBT) 1 - 140.3 122.7 225 286.7 350
Net income 1 148 101.5 150.5 189 230.3 292
Net margin - 11.71% 16.35% 16.49% 16.97% 17.95%
EPS 2 0.9400 0.6500 0.9600 1.180 1.440 1.830
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - 0.3000 - - -
Announcement Date 4/22/22 4/25/23 4/8/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 3.49% 5.03% 5.87% 6.73% 8.1%
ROA (Net income/ Total Assets) - - - 5.05% 5.65% -
Assets 1 - - - 3,743 4,077 -
Book Value Per Share 2 - 18.30 19.10 20.10 21.30 22.70
Cash Flow per Share 2 - 0.7500 1.250 1.870 2.100 3.080
Capex 1 - 96.3 101 43.5 52 -
Capex / Sales - 11.11% 10.97% 3.8% 3.83% -
Announcement Date 4/22/22 4/25/23 4/8/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Beijing Konruns Pharmaceutical Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.84 CNY
Average target price
44 CNY
Spread / Average Target
+47.45%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. Stock Beijing Konruns Pharmaceutical Co.,Ltd.
-21.64% 637M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603590 Stock
  4. Financials Beijing Konruns Pharmaceutical Co.,Ltd.